ALK and lung carcinoma: Despite study design biases and technical artifacts affecting single cancer biomarker history, they find applications in diagnosis (e.g., Bence-Jones protein in myeloma), prognosis (e.g., hCG in testicular cancer), and predicting treatment outcomes (e.g., ALK gene rearrangements guiding treatment in lung cancer).